Abstract

TICAGRELOR VERSUS ASPIRIN IN ACUTE STROKE OR TRANSIENT ISCHEMIC ATTACK: A STUDY.

Sujala Sunil, Vishnu Das* and Haripriya H.

ABSTRACT

Ticagrelor, the newer antiplatelet drug, may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with Transient Ischemic Attack. Its double-blind, controlled trial in which 13,199 patients with a non-severe ischemic stroke or high-risk transient ischemic attack who had not received intravenous or intraarterial thrombolysis and were not considered to have had a cardioembolic stroke were randomly assigned with a 1:1 ratio, to receive either ticagrelor or aspirin. The primary end point was the time to the occurrence of stroke, myocardial infarction, or death within 90 days. During the 90 days of treatment, a primary end-point event occurred in 442 of 6589 patients (6.7%) treated with ticagrelor and 497 of 6610 patients (7.5%) treated with aspirin. The study concluded that the patients with ticagrelor was not found to be superior to aspirin in reducing the risk of end points such as stroke, myocardial infarction, or death.

Keywords: Transient Ischemic Attack (TIA), intraartreial, cardioembolic, thrombolysis.